Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Triple Negative Breast Cancer|Ovarian Cancer|Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Stage IV Breast Cancer|Fallopian Tube Cancer|Peritoneal Cancer
Interventions: DRUG: niraparib|BIOLOGICAL: pembrolizumab
Sponsor: Tesaro, Inc.
Collaborators: Merck Sharp & Dohme LLC